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Introduction
============

Close to 200,000 cases of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) occur annually in the United States \[[@B1],[@B2]\]. It remains a leading cause of death in critically ill patients, with a mortality rate of approximately 30%, but as high as 60% in the elderly \[[@B1],[@B3],[@B4]\]. ARDS also represents a large societal burden, accounting for 3.6 million hospital days annually and significant long-term sequelae in survivors \[[@B1],[@B3]\]. These include various neuropsychological impairments (e.g. depression, cognitive decline), persistent weakness and pulmonary dysfunction, and decreased quality of life \[[@B3],[@B5]\].Unfortunately, the number of ARDS trials demonstrating improved clinical outcomes are far outnumbered by those that have not \[[@B6]-[@B21]\]. In patients with ARDS, the current body of evidence supports a lower tidal volume strategy as best practice \[[@B6]\].

In contrast, the optimal tidal volume in patients without ARDS is uncertain \[[@B22],[@B23]\]. Historically, it was thought that high tidal volume not only was safe, but also was preferred to avoid the hypoxia, atelectasis, and acidosis associated with mechanical ventilation with lower tidal volumes \[[@B24]-[@B26]\]. This led to the common use of tidal volumes in the 12- to 15-ml/kg range \[[@B27]\]. However, experimental data suggest that tidal volume is a major contributor to the development of lung injury \[[@B28]\]. Clinical data in intensive care unit (ICU) patients also suggests that larger tidal volume may contribute to the development of ARDS \[[@B29]-[@B31]\], suggesting that this syndrome may in part be preventable. However, this evidence has been inconclusive, because of observational trial design, small sample sizes, and lack of reproducibility in different patient populations \[[@B32],[@B33]\]. In patients without lung injury at the time of endotracheal intubation, progression to ARDS can occur over the course of hours and may increase mortality by \>30% \[[@B30],[@B34],[@B35]\]. This has led to increased interest in ARDS prevention and the examination of a lower tidal volume strategy to prevent its development in patients without lung injury.

We therefore aimed to systematically review the evidence regarding the role of tidal volume as a contributor to ARDS progression in patients without ARDS. The objectives of this study were to perform a systematic review of the literature comprising a comprehensive search strategy and standardized analysis techniques to determine whether lower tidal volumes, compared with higher tidal volumes, are associated with a decreased incidence of ARDS in mechanically ventilated patients. We hypothesized that lower tidal volume ventilation is associated with a decrease in progression to ARDS in mechanically ventilated patients, but the existing literature lacks the methodologic quality to provide definitive recommendations for the best tidal volume in patients without ARDS.

Materials and methods
=====================

This systematic review was designed, conducted, and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines \[[@B36],[@B37]\]. It did not require ethical approval from Washington University Human Research Protection Office. It is recognized that ALI and ARDS have undergone recent definitional change \[[@B38]\]. Although the definitional criteria in place during the systematic search for clinical trials, as well as the conduct of each study, was the American-European Consensus Conference (AECC) criteria, for consistency in reporting according to the new Berlin definition, we use the term ARDS to refer to both ARDS and ALI (as reported in previous literature) \[[@B2],[@B38]\].

Search for and identification of studies
----------------------------------------

We followed a written protocol (see Additional file [1](#S1){ref-type="supplementary-material"}) that was finalized before beginning the search. We initiated our timeline from 1967 (first description of ARDS) through 2011 and searched MEDLINE, EMBASE, CINAHL, and the Cochrane Library, by using a combination of standardized search terms and keywords covering the basic concepts of *acute lung injury, acute respiratory distress syndrome, mechanical ventilation, ventilator-induced lung injury, prevention, outcomes, and clinical trial*. A trained information professional experienced in systematic reviews assisted in designing the search strategy and in conducting the search. Two authors (BMF, NMM) also manually screened the reference lists of the articles selected for inclusion to identify additional studies. To identify potential unpublished data from clinical trials that have completed enrollment, BMF and NMM also (a) manually searched abstracts from the Society of Critical Care Medicine, European Society of Intensive Care Medicine, American Society of Anesthesiology, American Thoracic Society, CHEST, and the Society of Academic Emergency Medicine from 2008 to 2011; and (b) searched online for details of clinical trials registration (<http://ClinicalTrials.gov>). BMF also contacted principal investigators of published and unpublished studies for clarification of potential data for inclusion, as needed.

Inclusion criteria
------------------

Studies were eligible for review regardless of language or publication type. We included randomized controlled trials, prospective and retrospective cohort analyses, cross-sectional studies, and before-and-after trials of adults (older than 17 years) undergoing invasive positive-pressure ventilation without ARDS at the time of initiation of mechanical ventilation, and in which tidal volume was independently studied (either retrospectively or prospectively) as a predictor variable for outcome. We excluded studies involving patients with established ARDS by consensus criteria \[[@B2]\], studies of nonintubated patients (e.g. noninvasive positive-pressure ventilation), studies of one-lung ventilation, studies in which tidal volume was not the only ventilator variable studied or manipulated (e.g. tidal volume and positive end-expiratory pressure), and studies in which the development of ARDS was not a primary or secondary outcome measure. We also excluded articles that were reviews, correspondence, editorials, and nonhuman studies. We screened the reference list of all review articles to identify additional studies for inclusion. Corresponding authors were contacted, where appropriate, for clarification of data or study type.

Study selection and data abstraction
------------------------------------

Two reviewers (BMF and NMM) independently screened the titles and abstracts of identified studies for potential eligibility. After this relevance screen, full text articles were assessed for eligibility, and the two reviewers compared their exclusion logs to determine whether there was disagreement. All studies deemed potentially relevant after the screen were obtained, and the full manuscripts were reviewed for further exclusion. In cases of disagreement, a third reviewer (AD) assessed the study, and a consensus was reached between the three reviewers. Any disagreements in this collection were resolved with a consensus among the reviewers.

Assessment of study quality
---------------------------

We assessed the quality of clinical trials selected for inclusion by using the Cochrane Collaboration\'s tool for assessing the risk of bias in clinical trials, evaluating four domains: random sequence generation, concealment of allocation, blinding, and selective outcome reporting \[[@B39]\]. High quality was defined as a grade of A in at least three of the four methodology domains. For studies of observational design, each was assessed for its reporting of adherence to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement \[[@B40]\].

Assessment of publication bias
------------------------------

Because detecting publication bias is difficult, we sought to minimize bias through a medical librarian assisted comprehensive search strategy and the use of study registries. We planned to use a graphic display (funnel plot) of the size of the treatment effect against the precision of the trial to evaluate for potential publication bias \[[@B41]\].

Data analysis
-------------

Our original intent, after conducting the systematic review, was to conduct a meta-analysis of the data by using Review Manager (RevMan, Version 5.1, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). However, because of qualitative heterogeneity between the studies with respect to the patient populations studied and the baseline risk for ARDS development, this was not possible. RevMan was used to generate the funnel plot.

Results
=======

Search and selection
--------------------

The comprehensive search yielded a total of 1,704 potentially relevant publications. Details regarding the search, study selection, and reason for exclusion are shown in Figure [1](#F1){ref-type="fig"}.

![**Search, inclusion, and exclusion flow diagram**.](cc11936-1){#F1}

Inclusion
---------

After the relevance search, a complete manuscript review was performed on the remaining 52 articles. Thirteen studies were included in the final analysis \[[@B29]-[@B31],[@B34],[@B35],[@B42]-[@B49]\]. The characteristics of the included studies are shown in Table [1](#T1){ref-type="table"}.

###### 

Study characteristics

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Randomized controlled trial                                                                                                                                                                                                                                                                                                                          
  ----------------------------- --------- --------------------------------- -------------------------------------------------------- ---------------------------------------------------------------------- -------------------------- ----------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  **Author, year**              ***n***   **Intervention**                  **Location**                                             **Primary patient population**                                         **High-quality RCT?^a^**   **Primary outcome**                             **Secondary outcome**                                           **Comments^b^**

                                                                                                                                                                                                                                                                                                                                                       

  Determann, 2010               150       VT 6 ml/kg PBW vs. 10 ml/kg PBW   Medical/surgical ICU                                     Cardiac arrest, neurologic disease                                     YES                        Cytokine levels in BAL and plasma               Development of ARDS                                             Could be randomized up to 36 hours after mechanical ventilation

                                                                                                                                                                                                                                                                                                                                                       

  **Observational studies**                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                       

  **Cohort studies**                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                       

  **Author, year**              ***n***   **Study design**                  **Location**                                             **Primary patient diagnoses**                                          **High quality^c^**        **Primary outcome**                             **Secondary outcomes**                                          **Comments**

                                                                                                                                                                                                                                                                                                                                                       

  Gajic, 2004                   332       Retrospective                     Medical/surgical ICUs                                    Shock, sepsis                                                          NO                         Development of ARDS                             Hospital mortality, ventilator-free days                        Excluded patients ventilated \<48 hours

                                                                                                                                                                                                                                                                                                                                                       

  Gajic, 2005                   3,261     Retrospective                     Multicenter registry of medical/surgical ICUs            Postoperative, coma, pneumonia                                         NO                         Development of ARDS                             None mentioned                                                  Excluded patients ventilated \<48 hours

                                                                                                                                                                                                                                                                                                                                                       

  Kahn, 2006                    620       Retrospective                     Neuro ICU                                                Aneurysmal subarachnoid hemorrhage                                     NO                         Development of ARDS                             Incidence of lung-protective ventilation                        Tidal volume obtained from author contact.

                                                                                                                                                                                                                                                                                                                                                       

  Mascia, 2007                  82        Prospective                       Four European ICUs                                       Severe traumatic brain injury                                          NO                         Development of ARDS                             ICU LOS, VF days, ICU mortality                                 Excluded patients with ARDS \<24 hours from admission

                                                                                                                                                                                                                                                                                                                                                       

  Yilmaz, 2007                  375       Prospective, before-after         Medical/surgical ICU                                     Sepsis, pneumonia                                                      NO                         Development of ARDS                             Hospital mortality, duration of ventilation, ICU LOS, VF days   Excluded patients ventilated \<48 hours

                                                                                                                                                                                                                                                                                                                                                       

  Plurad, 2007                  2,346     Retrospective                     Surgical ICU                                             Trauma                                                                 NO                         Development of late ARDS                        Not mentioned                                                   Defined late ARDS as \>48 hours after admission

                                                                                                                                                                                                                                                                                                                                                       

  Iscimen, 2008                 160       Prospective                       Medical ICU                                              Septic shock                                                           NO                         Development of ARDS                             Hospital mortality, hospital length of stay                     

                                                                                                                                                                                                                                                                                                                                                       

  Jia, 2008                     789       Retrospective                     Medical/surgical/cardiac ICUs                            Unclear                                                                NO                         Development of ARDS                             Not mentioned                                                   Excluded patients ventilated \<48 hours. 341 patients had data missing on VT/PBW

                                                                                                                                                                                                                                                                                                                                                       

  Pasero, 2008                  200       Prospective                       Cardiac ICU                                              Patient status after cardiopulmonary bypass                            NO                         Development of ARDS                             Not mentioned                                                   Abstract only

                                                                                                                                                                                                                                                                                                                                                       

  Hughes, 2010                  89        Retrospective                     OR                                                       Abdominal, orthopedic, vascular surgery within 24 hours of ICU admit   NO                         Development of ARDS                             Not mentioned                                                   Assessed outcomes for 7 days.\
                                                                                                                                                                                                                                                                                                                                                       Excluded many risks for ARDS development

                                                                                                                                                                                                                                                                                                                                                       

  Blum, 2011                    53910     Retrospective                     OR: all noncardiothoracic and nontransplant procedures   ASA I, II                                                              NO                         Development of ARDS                             Not mentioned                                                   Abstract only

                                                                                                                                                                                                                                                                                                                                                       

  **Case-control study**                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                       

  **Author, year**              ***n***   **Study design**                  **Location**                                             **Primary patient diagnoses**                                          **High quality**           **Primary outcome**                             **Secondary outcomes**                                          **Comments**

                                                                                                                                                                                                                                                                                                                                                       

  Fernandez-Perez, 2009         4,420     Prospective, nested               OR with general anesthesia for ≥3 hours                  Elective operations                                                    NO                         Postoperative respiratory failure due to ARDS   Length of stay, 60-day survival, 1-year survival                Excluded patients with \"prevalent\" risk factors for ARDS. 1^st^hour ventilator variables were primary predictor variable
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^As assessed by Cochrane Collaboration\'s tool for assessing risk of bias in clinical trials. Was assigned a grade of \"A\" (high quality) in the following methodology domains: random-sequence generation, concealment of allocation, and selective outcome reporting; assigned a grade of \"C\" (unknown) in the following methodology domain: blinding. To explain, for trials in which blinding is not feasible at the point of intervention (such as a tidal volume trial), a grade of \"A\" would be assigned if the investigator collecting the primary outcome were blinded to the treatment allocation. ^b^For the RCT, there was no reported assessment of adherence to the ventilator/intervention protocol. ^c^As assessed by STROBE guidelines. ARDS, acute respiratory distress syndrome; ASA, American Society of Anesthesiologists; BAL, bronchoalveolar lavage; ICU, intensive care unit; LOS, length of stay; PBW, predicted body weight; VF, ventilator free; VT, tidal volume.

Study characteristics and outcomes reporting
--------------------------------------------

The 13 studies were published over a 7-year period (2004 through 2011). One study was a randomized controlled trial (RCT), and 12 were of observational trial design. On the methodologic quality assessment, the RCT was rated as high quality by Cochrane Collaboration\'s tool for assessing the risk of bias in clinical trials. In this trial, Grade A was given for random-sequence generation (sequence adequately generated), concealment of allocation (performed concealment allocation), and selective outcome reporting (free of suggestion of selective outcome reporting). For clinical trials in which blinding is not feasible at the point of intervention (potential methodologic issue for mechanical ventilation trials), high quality can still be assigned if the investigator collecting the primary outcome is blinded to the treatment allocation. This was unclear in the included RCT; therefore, a grade C was given for blinding (unknown whether investigators collecting the primary outcome were blinded to allocation). None of the 12 observational trials reported any adherence to the STROBE guidelines \[[@B40]\]. Two of the trials were multicenter studies (one retrospective registry and one prospective observational trial), and 11 were performed at a single center. Ten trials involved interventions and patients in medical, surgical, neurologic, trauma, or cardiac ICUs. Three trials were from the operating room. No studies examined mechanical ventilation in the Emergency Department (ED). Two of the studies were presented in abstract form only.

Significant heterogeneity was found with respect to the patient population studied and the diagnoses leading to respiratory failure (Table [1](#T1){ref-type="table"}). Examples include cardiac arrest, neurologic disorders such as subarachnoid hemorrhage and traumatic brain injury, postoperative patients, sepsis, and elective surgical patients. Visual inspection of the funnel plot (Figure [2](#F2){ref-type="fig"}) indicated potential publication bias, because observed asymmetry suggested unpublished research that favored not using low tidal volumes \[[@B41]\]. Although ARDS was defined according to the AECC criteria in each of the studies, differences existed in given criteria between studies \[[@B2]\]. For example, two studies required the criteria to be fulfilled for 2 consecutive days \[[@B29],[@B45]\]; one study required criteria for 24 hours \[[@B47]\]; one study required criteria for three consecutive arterial blood gases \[[@B31]\]; and one study allowed the criterion of left atrial hypertension to be determined at the discretion of the attending physician, \"with the modality of their choice,\" when a pulmonary artery catheter was not in use, yet provided no further information on the diagnostic modalities used \[[@B49]\]. Therefore, because of the very likely differences in baseline ARDS risk in the various studies\' populations, as well as the uncertainty of diagnostic accuracy for ARDS, given the variable criteria used to define it, a meta-analysis was not performed as had been planned *a priori*.

![**Funnel plot for assessment of publication bias**.](cc11936-2){#F2}

Clinical outcomes
-----------------

The results of the studies are shown in Table [2](#T2){ref-type="table"}. In the only RCT, a tidal volume of 6 ml/kg predicted body weight (PBW) was associated with an absolute risk reduction of 10.9% for the development of ARDS (number needed to treat of 9.2) when compared with 10 ml/kg PBW. The observational studies included three operating room studies (*n*= 58,419), one of which demonstrated an association between tidal volume and the development of ARDS. However, in this largest trial included (*n*= 53,910) in the review, the tidal volume difference between the two groups was not clinically significant (0.1 ml/kg PBW). Nine of the observational studies were from the ICU (*n*= 8,165), six of which showed tidal volume (mean tidal volume or indexed to PBW) to be an independent predictor of the development of ARDS. Five studies showed a dose-response relation to tidal volume, with the proportion of ARDS increasing with higher tidal volumes. No study reported adverse clinical effects in association with a lower tidal volume.

###### 

Study results

  Randomized controlled trial                                                                                                                                                                               
  ----------------------------- ------------------------ ------------------------------------------------------------- ---------------------------- -------------------------- ------------------ --------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Author, year**              **Time of ARDS onset**   **Incidence of ARDS**                                         **Experimental ARDS rate**   **Control ARDS rate**      **OR**             ***p***   **Comments^a^**
                                                                                                                                                                                                            
  Determann, 2010               1.9 days                 8% (*n*=12)                                                   2.6% (*n*= 2)                13.5% (*n*= 10)            5.1 (1.2-22.6)     0.01      Trial stopped early for safety, due to ARDS in control.
                                                                                                                                                                                                            
  **Observational studies**                                                                                                                                                                                 
                                                                                                                                                                                                            
  **Cohort studies**                                                                                                                                                                                        
                                                                                                                                                                                                            
  **Author, year**              **Time of ARDS onset**   **Incidence of ARDS**                                         **VT ARDS Group**            **VT No-ARDS Group**       **OR^b^**          ***p***   **Comments**
                                                                                                                                                                                                            
  Gajic, 2004                   2.5 days                 24% (*n*= 80)                                                 Unknown                      Unknown                    1.29 (1.12-1.51)   \<0.001   Proportion of ARDS increased as VT increased.
                                                                                                                                                                                                            
  Gajic, 2005                   Unknown                  6.2% (*n*= 205)                                               670 ml ± 220^c^              620 ml ±110 ^c^            1.26 (1.12-1.40)   \<0.001   Proportion of ARDS increased as VT increased.
                                                                                                                                                                                                            
  Kahn, 2006                    3 days                   27% (*n*= 170)                                                9.1 ml/kg PBW ±1.8           9.4 ml/kg PBW ±1.5         NS                 0.06      ARDS development associated with transfusion, SAH severity, and PRBC transfusion.
                                                                                                                                                                                                            
  Mascia, 2007                  2.8 days                 22% (*n*=18)                                                  10.4 ml/kg PBW ± 1.1^b^      9.5 ml/kg PBW ±1.0^c^      5.54 (1.54-9.24)   0.008     Proportion of ARDS increased as VT increased.
                                                                                                                                                                                                            
  Yilmaz, 2007║                 Unknown                  28% (*n*= 60) before protocol; 10% (*n*= 17) after protocol   Unknown                      Unknown                    1.31 (1.16-1.50)   \<0.001   Proportion of ARDS increased as VT increased.
                                                                                                                                                                                                            
  Plurad, 2007                  Unknown                  8.2% (*n*= 192)                                               8.6 ml/kg PBW ± 1.7          8.8 ml/kg PBW ± 2.3        NS                 0.383     ARDS associated with fluid balance and PRBC transfusion
                                                                                                                                                                                                            
  Iscimen, 2008                 5 hours                  44% (*n*= 71)                                                 6.9 ml/kg PBW (6.1-7.8)      7.0 ml/kg PBW (6.5-7.9)    NS                 0.362     Delayed antibiotics and resuscitation associated with ARDS
                                                                                                                                                                                                            
  Jia, 2008                     3.3 days                 19% (*n*= 152)                                                650.5 ml ± 119.7^c^          616.9 ml ± 112.8^c^        1.33 (1.09-1.62)   0.006     Proportion of ARDS increased as VT increased. Transfusion, fluid balance, airway pressures also associated with ARDS. Mean VT in patients that developed ARDS, 623.5 ml
                                                                                                                                                                                                            
  Pasero, 2008                  3.7 days                 7% (*n*= 14)                                                  Unknown                      Unknown                    2.04 (1.03-4.05)   0.042     Time of surgery and PEEP also associated with ARDS
                                                                                                                                                                                                            
  Hughes, 2010                  Unknown                  28% (*n*= 25)                                                 9.0 ml/kg PBW (8.3-10.0)     9.3 ml/kg PBW (8.3-10.1)   1.0 (0.3-3.2)      0.97      Intraoperative fluid \>20 ml/kg/h associated with ARDS
                                                                                                                                                                                                            
  Blum, 2011                    Unknown                  0.2% (*n*= 102)                                               9.2 ml/kg PBW^c^             9.1 ml/kg PBW^c^           0.77 (0.62-0.95)   0.02      PRBC transfusion strongest predictor of ARDS
                                                                                                                                                                                                            
  **Case-control study**                                                                                                                                                                                    
                                                                                                                                                                                                            
  **Author, year**              **Time of ARDS onset**   **Incidence of ARDS**                                         **VT ARDS Group**            **VT No-ARDS Group**       **OR^d^**          ***p***   **Comments**
                                                                                                                                                                                                            
  Fernandez-Perez, 2009         Unknown                  1.9% (*n*= 83)                                                8.9 ml/kg PBW ±1.6           8.7 ml/kg PBW ±1.7         1.03 (0.84-1.26)   0.801     Time of surgery, transfusion, and fluid balance associated with ARDS

ARDS, acute respiratory distress syndrome; NS, nonsignificant odds ratio (exact value and confidence interval not reported in original manuscript); OR, odds ratio; PEEP, positive end-expiratory pressure; PRBC, packed red blood cell; SAH, subarachnoid hemorrhage; VT, tidal volume. ^a^Each trial attempted to control for various factors associated with development with ARDS, either with statistical analysis or trial design (for the RCT). ^b^OR for risk of ARDS as a function of tidal volume. ^c^Statistically significant differences existed in VT between groups. ^d^Adjusted OR for VT between ARDS cases and matched controls. ^e^Protocol aimed at VT and transfusion reduction. VT 10.6 ml/kg PBW (9.0-12.1) before protocol versus 7.7 ml/kg PBW (6.7-9.0).

The time of ARDS onset was reported in seven studies, and occurred between days 2 and 4 (5 hours to 3.7 days). The incidence of ARDS was very low in the two operating room studies involving primarily elective procedures: 0.2% and 1.9%. This is in contrast to a much higher incidence in ICU patients, ranging from 6.2% to 44%.

In the studies comparing secondary outcomes between ARDS and non-ARDS groups, the development of ARDS increased mortality and morbidity. ARDS was associated with an absolute increase in mortality of up to 36%, increased ICU and hospital lengths of stay, fewer ventilator-free days, and increased organ failure (Table [3](#T3){ref-type="table"}).

###### 

Clinical outcomes comparing ARDS and non-ARDS groups

  Outcome                 Author, year            ARDS           No ARDS   *p*
  ----------------------- ----------------------- -------------- --------- ---------
  Mortality               Kahn, 2006              42%            19%       \<0.05
                                                                           
                          Fernandez-Perez, 2009   44%            8%        \<0.001
                                                                           
                          Mascia, 2007            28%            22%       NS
                                                                           
  Hospital mortality      Gajic, 2004             34%            24%       0.116
                                                                           
                          Gajic, 2005             62%            32%       
                                                                           
                          Iscimen, 2008           51%            18%       \<0.001
                                                                           
                          Fernandez-Perez, 2009   17%            5%        0.004
                                                                           
  ICU mortality           Iscimen, 2008           38%            11%       
                                                                           
  ICU LOS (days)          Mascia, 2007            25             20        \<0.05
                                                                           
                          Kahn, 2006              15% increase             \<0.05
                                                                           
  Hospital LOS (days)     Kahn, 2006              7% increase              NS
                                                                           
                          Fernandez-Perez, 2009   17             5         \<0.001
                                                                           
  VF days                 Gajic, 2004             17             22        0.007
                                                                           
                          Mascia, 2007            11             16        \<0.05
                                                                           
  Duration of MV (days)   Kahn, 2006              14             8         \<0.001
                                                                           
  Renal failure           Kahn, 2006              8%             2%        \<0.001

ARDS, acute respiratory distress syndrome; LOS, length of stay; MV, mechanical ventilation; NS, nonsignificant; VF, ventilator free.

Discussion
==========

In patients who do not have ARDS at the time of endotracheal intubation, the preponderance of evidence implies an association between lower tidal volume and subsequent progression to ARDS. However, this systematic review could yield no definitive recommendations regarding the most appropriate tidal volume strategy in patients without ARDS. Several important caveats exist. An overall lack of data appears in the existing body of literature, as well as a lack of methodologic quality in the data that do exist. Of the 13 trials included in this review, only one was a high quality RCT, whereas the remainder were of observational trial design. None of the observational trials referenced the STROBE guidelines, which are endorsed by 110 journals worldwide \[[@B50]\]. Publication guidelines like STROBE were designed to standardize the reporting of medical research to enhance transparency and minimize variability \[[@B51]\]. An increasing body of evidence indicates that the guidelines do improve the overall quality of research reporting \[[@B52]\].

There was also substantial heterogeneity appeared in the patient populations examined, each carrying perhaps vastly different risk for ARDS progression. For example, relatively healthy patients with a finite exposure to tidal volume risk (operating room cases) are inherently different in risk for progression compared with critically ill ICU patients \[[@B53]\]. Furthermore, even among the studies restricted to patients with longer exposure to tidal volume (ICU patients), the diagnoses leading to mechanical ventilation (Table [1](#T1){ref-type="table"}) also carry very different risk for ARDS (e.g. septic shock versus postoperative). Funnel-plot inspection for the assessment of publication bias revealed asymmetry suggestive of publication bias. However, asymmetric funnel plots are not sufficient proof of publication bias. Other potential explanations for asymmetry include study-to-study heterogeneity with the intervention fidelity or outcome assessment. Also, improvement in the usual care in the \"control\" treatment groups as routine management evolves over time may reduce the observed effect size. It is also possible that an asymmetric funnel plot is the result of chance alone \[[@B41]\]. Finally, differences were noted between studies in how a patient was classified as having developed ARDS, even though each study required fulfillment of accepted consensus criteria \[[@B2]\].

The results of this systematic review do reveal some important trends in the data. First, each study that reported ARDS onset showed that it occurs early in mechanically ventilated at-risk patients. This may reflect the difficulty in defining the precise onset of ARDS retrospectively, but also that many mechanically ventilated patients may have early ARDS that has yet to manifest clinically. This suggests that prevention trials should target the most immediate time after initiation of mechanical ventilation (e.g. in the ED, interhospital transport, and/or the first 24 hours of ICU admission). Endotracheal intubation and initiation of mechanical ventilation is a common occurrence in the ED, yet the effect that ED-based mechanical ventilation may have on outcome has not been studied \[[@B54]\]. However, preenrollment data from ARDS clinical trials showed that early tidal volume did not influence mortality, further highlighting the equipoise on this topic \[[@B55]\].

Second, the incidence of ARDS is very low when tidal volume is studied in low risk patients in the operating room (\<2%). This is in contrast to the ICU, where the progression to ARDS appears to be a significant problem (as high as 44%). However, in a cohort of higher-risk surgical patients, higher tidal volumes have been associated with other clinical outcomes, including greater nonpulmonary organ failure and an increase in duration of mechanical ventilation and ICU length of stay \[[@B56]\].

Third, although no definitive conclusions between tidal volume and progression to ARDS can be made, based on this systematic review, several findings in this body of evidence suggest a link between higher tidal volumes and progression to ARDS. Although almost all of the data are observational trials, consistent findings across trial design suggest a cause-effect relation \[[@B57]\]. In the only RCT examining this topic to date, tidal volume was predictive of progression to ARDS. Additionally, the majority of the observational data demonstrate an increased ARDS incidence with larger tidal volumes, which also suggests a causal link \[[@B57]\]. A dose-response relation (seen in five studies), with the proportion of ARDS patients increasing with higher tidal volumes, suggests cause-effect, as does the fact that no findings appeared in the opposite direction (no study showed lower tidal volumes to be harmful).

Fourth, the development of ARDS was associated with many other factors across these trials. These include patient-related (e.g. restrictive lung disease \[[@B29]\]), ventilator-related (e.g. airway pressure \[[@B47]\]), and non ventilator-related (e.g. fluid balance and transfusion \[[@B35],[@B45],[@B47],[@B49]\]) factors. This further highlights that the development of ARDS reflects an interaction between patient risk and treatment variables, which was demonstrated before, and suggests that the most effective ARDS-prevention strategy may involve a multimodal approach (e.g. early resuscitation, fluid management and type, lower tidal volume, high transfusion threshold, and so on) \[[@B48],[@B53]\]. In addition, future ARDS-prevention trials will need to control for each of these confounding variables while assessing patient populations with similar baseline risk of progressing to ARDS.

Finally, the progression to ARDS is associated with significant increase in morbidity and mortality. In all trials directly comparing ARDS versus no-ARDS groups, mortality (up to fivefold increase), length of stay, and organ failure were all increased with the development of the syndrome. Although the best strategy to prevent the progression to ARDS has not been fully elucidated, it is clear that its prevention should be a high priority in clinical care and further research \[[@B58]\].

Important limitations exist in this systematic review. The only RCT was stopped early, after an unplanned interim analysis, because of safety concerns of ARDS development in the 10-ml/kg PBW group \[[@B44]\]. Clinical trials stopped early for benefit are increasing in prevalence, often lack information on why the trial was stopped, and routinely show larger than expected treatment effects \[[@B59]\]. The benefit of clinical trials stopped early, including the trial in this review, should therefore be viewed with caution. However, with 75% of the planned enrollment achieved, and a very significant between-group difference for the primary outcome (*p*= 0.01), confidence is increased that these results are indeed valid.

Second, relatively few studies have examined ARDS prevention and the role of tidal volume in the development of ARDS. Existing studies are limited by their observational trial design, and therefore any attempt to analyze these studies as a group is limited by their individual weaknesses.

Third, a meta-analysis of these data could not be conducted as planned *a priori*, which differs from another systematic review on this topic \[[@B60]\]. The patients were not qualitatively similar and represent a spectrum of patients from those with very little risk for ARDS (e.g. elective surgery patients) to those with very high risk (e.g. septic shock). When contemplating whether a systematic review should become a meta-analysis, heterogeneity is typically first addressed on a macroscopic level of the individual study\'s design, population, intervention(s), and outcome measures. If sufficient differences exist between individual studies such that lumping them together is comparing \"apples and oranges,\" then a meta-analysis is not appropriate. Systematic review authors should proceed to meta-analysis only if this first level of heterogeneity is assessed and deemed unlikely, an approach that has been previously advocated \[[@B61]\]. We were therefore able to conduct only a qualitative analysis of the data, as conducting a meta-analysis would have served only to homogenize patients artificially. We recognize that these limitations make drawing recommendations difficult based on this systematic review, but with our inclusion of an additional 10 studies (and \>7,000 ICU patients) and strict adherence to reporting guidelines, we believe this current review to be the most complete and methodologically sound assessment of the literature to date.

The focus on early mechanical ventilation and ARDS prevention is likely to increase. Recently the National Heart, Lung and Blood Institute (NHLBI) recommended the development of ARDS prevention trials, as well as observational trials of patients without ARDS undergoing prolonged mechanical ventilation \[[@B58]\]. Given the limited treatment options for ARDS, the period of mechanical ventilation immediately after endotracheal intubation is emerging as a critical time window of clinical care and an opportunity for clinical trials to improve outcome \[[@B58]\]. Our results are important in further highlighting knowledge gaps, which may serve in the future design of ARDS prevention trials, and not only call attention to the limitation of the literature, but also highlight potential solutions for clinical trials going forward. This includes RCTs targeting homogeneous patient groups with higher event rates for ARDS progression and early timing of trial enrollment (e.g. immediately after endotracheal intubation in the ED). Factorial trial design aimed at limiting more than one risk modifier for ARDS progression, such as tidal volume and fluid balance, should be considered to maximize efficiency in this research arena \[[@B62]\]. Future research should aim to minimize bias by incorporating publishing guidelines such as the Consolidated Standards of Reporting Trials (CONSORT) for RCTs and the STROBE for observational trials and should have clinically relevant end points, such as progression to ARDS or development of nonpulmonary organ failure as a surrogate for ventilator-associated lung injury \[[@B40],[@B63],[@B64]\]. Finally, to reduce efficiently the preventable heterogeneity and variability in research and clinical care in a sustainable fashion, interventions should be simple, and reproducibility should be enhanced with the aid of implementation science and electronic aids \[[@B65]-[@B69]\]. Knowledge of factors influencing a lack of adherence to beneficial therapy in ARDS may aid clinicians in translating research to routine care for prevention of the syndrome as well \[[@B65],[@B70]\]. These trials will ultimately influence clinicians and change practice. Therefore, analyzing critically what has and has not been done is of vital importance.

Conclusions
===========

Currently, no definitive recommendations can be made on the most appropriate tidal volume strategy in mechanically ventilated patients without ARDS. Data suggest an increased incidence of ARDS with higher tidal volumes, but previous studies are limited by their heterogeneity and high variability in baseline ARDS risk among the patients included. Given the increased mortality and morbidity associated with progression to ARDS, a focus on prevention should remain a high priority for future research and clinical practice.

Key messages
============

• The majority of data suggest that higher tidal volumes are causal in the development of ARDS.

• An overall lack of quality data prevents a definitive recommendation for the most appropriate tidal volume in patients with ARDS.

• ARDS occurs early in the course of mechanical ventilation, suggesting that ARDS-prevention trials should occur early in the course of mechanical ventilation, such as in the emergency department.

• The development of ARDS is associated with significant increases in mortality and morbidity, suggesting that ARDS-prevention trials are needed.
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